TY - JOUR
T1 - Enterobacteria-mediated deconjugation of taurocholic acid enhances ileal farnesoid X receptor signaling
AU - Kuribayashi, Hideaki
AU - Miyata, Masaaki
AU - Yamakawa, Hiroki
AU - Yoshinari, Kouichi
AU - Yamazoe, Yasushi
N1 - Funding Information:
This study was supported by the Ministry of Education, Culture, Sports Science, and Technology of Japan [Grants 21390039 ]; the Mishima Kaiun Memorial Foundation.
PY - 2012/12/15
Y1 - 2012/12/15
N2 - Enterobacteria are known to deconjugate amino acid-conjugated bile acids in the intestine. Administration of ampicillin (ABPC; 3 days, 100 mg/kg) decreased the expression of ileal farnesoid X receptor (Fxr) target genes, and increased the levels of total bile acids in the intestinal lumen. The primary tauro-conjugates of cholic acid (TCA) and beta-muricholic acid (TβMCA) levels were increased, whereas the primary unconjugates, cholic acid (CA) and beta-muricholic acid (βMCA), levels decreased to below detectable levels (<0.01 μmol) in ABPC-treated mice. The effects of individual bile acid on expression of the ileal farnesoid X receptor target genes were examined in ABPC-treated mice. The expression of ileal farnesoid X receptor target genes in ABPC-treated mice was clearly enhanced after CA (500 mg/kg), but not TCA (500 mg/kg) cotreatment. Their levels in control mice were enhanced after either CA or TCA-cotreatment. Unconjugated CA levels in the intestinal lumen and portal vein were increased in both ABPC-treated and control mice. Reduced ileal Fgf15 and Shp mRNA levels in ABPC-treated mice were also increased after CA (100 mg/kg) cotreatment at which luminal CA levels was restored to the level in controls, but was unaffected by βMCA (100 mg/kg) cotreatment. In addition, no increase in ileal Shp, Ibabp or Ostα mRNA levels was observed even after CA (500 mg/kg) cotreatment in ABPC-treated farnesoid X receptor-null mice despite increased CA levels in the intestinal lumen. These results suggest the role of enterobacteria in bile acid-mediated enhancement of ileal farnesoid X receptor signaling by TCA deconjugation.
AB - Enterobacteria are known to deconjugate amino acid-conjugated bile acids in the intestine. Administration of ampicillin (ABPC; 3 days, 100 mg/kg) decreased the expression of ileal farnesoid X receptor (Fxr) target genes, and increased the levels of total bile acids in the intestinal lumen. The primary tauro-conjugates of cholic acid (TCA) and beta-muricholic acid (TβMCA) levels were increased, whereas the primary unconjugates, cholic acid (CA) and beta-muricholic acid (βMCA), levels decreased to below detectable levels (<0.01 μmol) in ABPC-treated mice. The effects of individual bile acid on expression of the ileal farnesoid X receptor target genes were examined in ABPC-treated mice. The expression of ileal farnesoid X receptor target genes in ABPC-treated mice was clearly enhanced after CA (500 mg/kg), but not TCA (500 mg/kg) cotreatment. Their levels in control mice were enhanced after either CA or TCA-cotreatment. Unconjugated CA levels in the intestinal lumen and portal vein were increased in both ABPC-treated and control mice. Reduced ileal Fgf15 and Shp mRNA levels in ABPC-treated mice were also increased after CA (100 mg/kg) cotreatment at which luminal CA levels was restored to the level in controls, but was unaffected by βMCA (100 mg/kg) cotreatment. In addition, no increase in ileal Shp, Ibabp or Ostα mRNA levels was observed even after CA (500 mg/kg) cotreatment in ABPC-treated farnesoid X receptor-null mice despite increased CA levels in the intestinal lumen. These results suggest the role of enterobacteria in bile acid-mediated enhancement of ileal farnesoid X receptor signaling by TCA deconjugation.
KW - Antibiotics
KW - Bile acid
KW - Deconjugation
KW - Enterobacteria
KW - Farnesoid X receptor (Fxr)
UR - http://www.scopus.com/inward/record.url?scp=84869503270&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84869503270&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2012.09.048
DO - 10.1016/j.ejphar.2012.09.048
M3 - Article
C2 - 23051670
AN - SCOPUS:84869503270
SN - 0014-2999
VL - 697
SP - 132
EP - 138
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 1-3
ER -